Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Short-term Investments (2021 - 2025)

Historic Short-term Investments for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $177.2 million.

  • Kiniksa Pharmaceuticals International's Short-term Investments rose 4022.02% to $177.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.2 million, marking a year-over-year increase of 4022.02%. This contributed to the annual value of $60.0 million for FY2024, which is 3898.82% down from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Short-term Investments stood at $177.2 million, which was up 4022.02% from $115.7 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Short-term Investments ranged from a high of $177.2 million in Q3 2025 and a low of $10.0 million during Q3 2021
  • In the last 5 years, Kiniksa Pharmaceuticals International's Short-term Investments had a median value of $82.3 million in 2022 and averaged $86.0 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Short-term Investments tumbled by 4294.68% in 2022, and later soared by 23351.76% in 2023.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Short-term Investments stood at $59.7 million in 2021, then rose by 13.66% to $67.9 million in 2022, then surged by 44.96% to $98.4 million in 2023, then crashed by 38.99% to $60.0 million in 2024, then soared by 195.18% to $177.2 million in 2025.
  • Its last three reported values are $177.2 million in Q3 2025, $115.7 million for Q2 2025, and $111.2 million during Q1 2025.